Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

The Food and Drug Administration approved Novo Nordisk's popular weight-loss drug Wegovy to treat a [form of liver disease]( ...

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

The Ozempic price cut could appease US President Donald Trump, who has pushed for drug companies to lower their prices.

Novo Nordisk A/S innovation and growth continue to shine. Now, it has a partnership with GoodRX Holdings. Click for my ...

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) ...

Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...